1. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.

    JAMA Dermatology 151(2):195 (2015) PMID 25321335

    Ipilimumab, a human monoclonal antibody targeted against cytotoxic T-lymphocyte antigen 4, has shown promise in the treatment of metastatic melanoma. However, given its mechanism of action, immune-related adverse effects have been reported with this therapy. Despite increasing reports of immune-...
  2. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.

    JAMA Dermatology 151(2):195 (2015) PMID 25321335

    Ipilimumab, a human monoclonal antibody targeted against cytotoxic T-lymphocyte antigen 4, has shown promise in the treatment of metastatic melanoma. However, given its mechanism of action, immune-related adverse effects have been reported with this therapy. Despite increasing reports of immune-...
  3. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.

    Arthritis Care And Research 66(8):1246 (2014) PMID 24470436 PMCID PMC4467535

    Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with rheumatoid arthritis (RA). We examined the effect of HCQ on insulin resistance in subjects without diabetes mellitus with stable RA. Twenty-three RA subjects not curre...
  4. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.

    Arthritis Care And Research 66(8):1246 (2014) PMID 24470436

    Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with rheumatoid arthritis (RA). We examined the effect of HCQ on insulin resistance in subjects without diabetes mellitus with stable RA. Twenty-three RA subjects not curre...
  5. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.

    International Journal of Rheumatic Diseases 17(4):359 (2014) PMID 24460872

    Rheumatoid arthritis (RA) can be the source of significant pain and functional limitation. The past 20 years have seen a transition in treatment goals away from mere pain management toward disease modification through the suppression of autoimmunity. Disease-modifying anti-rheumatic drugs, such ...
  6. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.

    International Journal of Rheumatic Diseases 17(4):359 (2014) PMID 24460872

    Rheumatoid arthritis (RA) can be the source of significant pain and functional limitation. The past 20 years have seen a transition in treatment goals away from mere pain management toward disease modification through the suppression of autoimmunity. Disease-modifying anti-rheumatic drugs, such ...
  7. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.

    International Journal of Rheumatic Diseases 17(4):359 (2014) PMID 24460872

    Rheumatoid arthritis (RA) can be the source of significant pain and functional limitation. The past 20 years have seen a transition in treatment goals away from mere pain management toward disease modification through the suppression of autoimmunity. Disease-modifying anti-rheumatic drugs, such ...
  8. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.

    Arthritis & rheumatology (Hoboken, N.J.) 66(3):768 (2014) PMID 24574239

  9. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.

    Arthritis & rheumatology (Hoboken, N.J.) 66(3):768 (2014) PMID 24574239

  10. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor.

    Arthritis & Rheumatism 63(4):894 (2011) PMID 21305505

    Serum rheumatoid factor (RF) and other heterophilic antibodies potentially interfere with antibody-based immunoassays by nonspecifically binding detection reagents. The purpose of this study was to assess whether these factors confound multiplex-based immunoassays, which are used with increasing...
  11. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor.

    Arthritis & Rheumatism 63(4):894 (2011) PMID 21305505

    Serum rheumatoid factor (RF) and other heterophilic antibodies potentially interfere with antibody-based immunoassays by nonspecifically binding detection reagents. The purpose of this study was to assess whether these factors confound multiplex-based immunoassays, which are used with increasing...
  12. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development.

    Journal of Experimental Medicine 206(10):2151 (2009) PMID 19752183 PMCID PMC2757870

    The unfolded protein response (UPR) is a stress response pathway that is driven by the increased load of unfolded proteins in the endoplasmic reticulum of highly secretory cells such as plasma cells (PCs). X box binding protein 1 (XBP1) is a transcription factor that mediates one branch of the U...
  13. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development.

    Journal of Experimental Medicine 206(10):2151 (2009) PMID 19752183 PMCID PMC2757870

    The unfolded protein response (UPR) is a stress response pathway that is driven by the increased load of unfolded proteins in the endoplasmic reticulum of highly secretory cells such as plasma cells (PCs). X box binding protein 1 (XBP1) is a transcription factor that mediates one branch of the U...
  14. Dyspnoea in a young woman with active systemic lupus erythematosus.

    Lupus 18(9):777 (2009) PMID 19578101

    Diffuse alveolar haemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). We present the case of a 24-year-old Cambodian woman with SLE followed in the Brigham and Women's Hospital Lupus Center in Boston, Massachusetts. She presented with dyspnoea and ...
  15. Dyspnoea in a young woman with active systemic lupus erythematosus.

    Lupus 18(9):777 (2009) PMID 19578101

    Diffuse alveolar haemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). We present the case of a 24-year-old Cambodian woman with SLE followed in the Brigham and Women's Hospital Lupus Center in Boston, Massachusetts. She presented with dyspnoea and ...
  16. Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.

    Arthritis & Rheumatism 58(8):2585 (2008) PMID 18668572

  17. Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.

    Arthritis & Rheumatism 58(8):2585 (2008) PMID 18668572

  18. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.

    Current Rheumatology Reports 10(3):195 (2008) PMID 18638427

    Nephrogenic systemic fibrosis is a devastating systemic fibrosing disorder that afflicts patients with renal dysfunction. Growing evidence supports the hypothesis that gadolinium-containing contrast agents (GCCAs) trigger the development of nephrogenic systemic fibrosis. Hence, this condition is...
  19. Oral versus parenteral administration of methotrexate for the treatment of active RA.

    Nature Clinical Practice Rheumatology 4(7):342 (2008) PMID 18521111

  20. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.

    Current Rheumatology Reports 10(3):195 (2008) PMID 18638427

    Nephrogenic systemic fibrosis is a devastating systemic fibrosing disorder that afflicts patients with renal dysfunction. Growing evidence supports the hypothesis that gadolinium-containing contrast agents (GCCAs) trigger the development of nephrogenic systemic fibrosis. Hence, this condition is...